AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Fenebrutinib (GDC-0853, RG7845): An Orally Administered Bruton’s tyrosine Kinase (BTK) Inhibitor Designed to Block B Cell Proliferation - Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com

December 23, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Dec 23, 2020--

The “FENEBRUTINIB - Emerging Insight and Market Forecast - 2030” report has been added to ResearchAndMarkets.com’s offering.

ADVERTISEMENT

“FENEBRUTINIB- Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the FENEBRUTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

Fenebrutinib (GDC-0853, RG7845) is an orally administered Bruton’s tyrosine kinase (BTK) inhibitor designed to block B cell proliferation and the resulting excessive immune response seen in autoimmune disorders.

Scope of the Report

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around FENEBRUTINIB.
  • The report contains forecasted sales for FENEBRUTINIB till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Chronic Spontaneous Urticaria.
  • The report also features the SWOT analysis with analyst insights and key findings of FENEBRUTINIB.

ADVERTISEMENT

FENEBRUTINIB Analytical Perspective

In-depth FENEBRUTINIB Market Assessment

This report provides a detailed market assessment of FENEBRUTINIB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

FENEBRUTINIB Clinical Assessment

The report provides the clinical trials information of FENEBRUTINIB covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for Chronic Spontaneous Urticaria is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence FENEBRUTINIB dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Chronic Spontaneous Urticaria are giving market competition to FENEBRUTINIB and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of FENEBRUTINIB.
  • The in-depth analysis of the forecasted sales data of FENEBRUTINIB from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FENEBRUTINIB.

Key Questions Answered

  • Which company is developing FENEBRUTINIB along with the phase of the clinical study?
  • What is the technology utilized in the development of FENEBRUTINIB?
  • What is the product type, route of administration and mechanism of action of FENEBRUTINIB?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FENEBRUTINIB development?
  • What are the key designations that have been granted to FENEBRUTINIB?
  • What is the forecasted market scenario of FENEBRUTINIB?
  • What is the history of FENEBRUTINIB and what is its future?
  • What is the forecasted sales of FENEBRUTINIB in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to FENEBRUTINIB?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

For more information about this report visit https://www.researchandmarkets.com/r/ngih53

View source version on businesswire.com:https://www.businesswire.com/news/home/20201223005442/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 12/23/2020 12:29 PM/DISC: 12/23/2020 12:29 PM

http://www.businesswire.com/news/home/20201223005442/en